News | February 03, 2026
Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Subscribe To Our Newsletter & Stay Updated
